Miller Denis R
PAREXEL International, Waltham, MA 02451, USA.
Br J Haematol. 2006 Jul;134(1):20-6. doi: 10.1111/j.1365-2141.2006.06119.x.
Sidney Farber, world-renowned paediatric pathologist, made major contributions to his field but is acknowledged as the father of the modern era of chemotherapy. He recognised that folic acid stimulated leukaemic cell growth and enhanced disease progression. He hypothesised that folic acid antagonists would inhibit or arrest the proliferation of cancer cells. His landmark study, published in 1948, demonstrated that a number of folic acid antagonists, including 4-aminopteroyl-glutamic acid (aminopterin) produced temporary remissions in children with acute undifferentiated leukaemia. These observations lead to the development and use of other chemotherapeutic agents, either singly or, more effectively, in combination for treating childhood and adult malignancies. He introduced actinomycin D for the treatment of metastatic and localised Wilms tumour. Under his guidance and leadership, both the 'Jimmy Fund', one of the first comprehensive paediatric oncology treatment centres, and the Children's Cancer Research Foundation, which later became the Dana-Farber Cancer Institute, were founded.
西德尼·法伯是世界著名的儿科病理学家，他在自己的领域做出了重大贡献，但被誉为现代化疗时代之父。他认识到叶酸会刺激白血病细胞生长并加速疾病进展。他推测叶酸拮抗剂会抑制或阻止癌细胞增殖。他于1948年发表的具有里程碑意义的研究表明，包括4-氨基蝶酰谷氨酸（氨甲蝶呤）在内的多种叶酸拮抗剂能使急性未分化白血病患儿实现暂时缓解。这些观察结果促使了其他化疗药物的研发和使用，这些药物单独使用，或者更有效地联合使用，用于治疗儿童和成人恶性肿瘤。他引入放线菌素D来治疗转移性和局限性肾母细胞瘤。在他的指导和领导下，第一个综合性儿科肿瘤治疗中心之一“吉米基金”以及后来成为丹娜-法伯癌症研究所的儿童癌症研究基金会得以成立。
